Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Solid Tumor, Miscellaneous × pemigatinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Cholangiocarcinoma 6 Carcinoma, Transitional Cell 5 Acrocephalosyndactylia 5 Neoplasm Metastasis 3 Gastrointestinal Neoplasms 3 Breast Neoplasms 3 Recurrence 2 Pancreatic Neoplasms 2 Colorectal Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Carcinoma 2 Urinary Bladder Neoplasms 1 Stomach Neoplasms 1 Solid Tumor, Miscellaneous 1 Solid Tumor 1 Sarcoma 1 Oligodendroglioma 1 Non-Muscle Invasive Bladder Neoplasms 1 Neoplasms, Unknown Primary 1 Myeloproliferative Disorders 1 Lymphoma, Mantle-Cell 1 Lymphoma, B-Cell, Marginal Zone 1 Lymphoma, B-Cell 1 Lung Neoplasms 1 Locally Advanced Unresectable Gastric Cancer 1 Hematologic Neoplasms 1 Glioma 1 Glioblastoma 1 Gastrointestinal Stromal Tumors 1 Eosinophilia 1

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06653777 2025-06-05

AcSé PEMI

UNICANCER

Phase 2 Recruiting

Other solid neoplasm

Solid Tumor, Miscellaneous

Data powered by HemOnc (CC BY 4.0) Colophon ⚡